Conference MDAngle: ASCO 2025 Advanced NSCLC
ASCO 2025: Previewing Therapeutic Updates in Advanced NSCLC
Dr Preeshagul notes how excitement is building around new therapies for advanced NSCLC at ASCO 2025, especially for KRAS G12C, EGFR exon 20 insertions, and HER2 alterations, with several promising studies such as LOXO-RAS-20001 and zipalertinib monotherapy drawing attention. Emerging HER2-targeted small molecules such as zongertinib and BAY 2927088 are also being closely watched for their potential central nervous system activity. Additionally, antibody-drug conjugates such as those in the TROPION-Lung02 trial are generating interest for their potential roles across treatment lines. Quick Clinical Takeaways
Coming soon: Dr Preeshagul highlights new data and progress regarding advanced NSCLC immediately following ASCO. How Will My Patients Benefit?
Coming soon: Reflections from Dr Preeshagul on how new data from ASCO will affect her patients with advanced NSCLC. Image 1: Memorial Sloan Kettering Cancer Center
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
4 minutes ago
- Yahoo
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting
We recently published . Bausch Health Companies Inc. (NYSE:BHC) is one of the best-performing stocks on Monday. Bausch Health bounced back by 15.83 percent on Monday to close at $6.66 apiece as investors appeared to have hunted for bargains, having traded below the $6 level for seven days in a row. Monday's share price marked Bausch Health Companies Inc. (NYSE:BHC) first official claw back to the green territory since the start of the month after hovering for most of the trading days below the $5.89 closing price on July 31. It picked up to $5.94 on August 5, but only by a slight 0.85-percent gain from July 31's closing price. Year-to-date, the company's shares were down by 17.4 percent. In recent news, Bausch Health Companies Inc. (NYSE:BHC) expanded its attributable net income by 1,380 percent in the second quarter of the year to $148 million from only $10 million in the same period last year. Revenues also grew by 5 percent to $2.53 billion from $2.4 billion. Copyright: nimon / 123RF Stock Photo For the full-year period, Bausch Health Companies Inc. (NYSE:BHC) raised its revenue guidance to $10 billion to $10.25 billion, as compared with the $9.95 billion to $10.2 billion previously. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Tyrant
6 minutes ago
- Geek Tyrant
Alan Tudyk Says He Was Cut From I, ROBOT Marketing After Testing Better Than Will Smith in Test Screenings — GeekTyrant
Alan Tudyk just revealed a wild behind the scenes story from his time on the 2004 sci-fi blockbuster I, Robot , and it explains why so many people still don't know he was in it. Appearing on the Toon'd In with Jim Cummings podcast, Tudyk said he was dropped from the film's marketing campaign after test screenings showed he was scoring higher with audiences than the movie's leading man, Will Smith. Tudyk brought the robot Sonny to life through motion capture and voice work, but after the studio saw the test results, he claims they decided to make his involvement… vanish. 'A lot of people did not know I did Sonny the Robot in I, Robot , and there is a reason. They were doing test audiences for the movie, and they score the characters in this kind of test screening. 'I got word back: 'Alan, you are testing higher than Will Smith.' And then I was gone. I was done. There was no publicity, and my name was not mentioned.' The actor admitted the move blindsided him. 'I was so shocked. I was like, 'Wait, nobody is going to know I'm in it!' I put a lot into [that performance]. I had to move like a robot. At the time, I was very upset.' He totally has a right to be upset over that! What a crappy thing for the studio to do to an actor! I, Robot was directed by Alex Proyasand is set in 2035, it follows Smith's Chicago detective investigating the suspicious death of a robotics company founder. While society's highly intelligent robots are meant to serve humanity, Smith's character suspects one of them, Sonny, of murder. The cast also featured Bridget Moynahan, Bruce Greenwood, James Cromwell, and Chi McBride. Back in 2004, motion capture was still a relatively fresh tool in Hollywood. Aside from characters like Jar Jar Binks in Star Wars and Gollum in The Lord of the Rings , audiences hadn't seen much of it. Tudyk's work as Sonny helped push that technology forward, and he later became a fan favorite as the sarcastic droid K-2SO in Rogue One: A Star Wars Story and its Disney+ prequel series Andor . It's been over 20 years since I, Robot hit theaters, but for many fans, this might be the first time they're realizing Sonny's soul came from Alan Tudyk. Turns out, the reason they didn't know… was by design. I mean, you can't have Tudyk being better than Will Smith! Sheesh. That movie would've been so much better without Smith.
